Imposter phenomenon is a frequent experience among U.S. physicians, and disappointment in present accomplishments is more common in physicians than in other professions, according to the results of a national survey. “Imposter phenomenon” (IP) describes the experience of a high-achieving person who feels as though their success was undeserved and who maintains feelings of self-doubt despite evidence of ability and achievement. Researchers surveyed physicians across the United States to understand the prevalence and consequences of IP, and the results of the study were published in an issue of Mayo Clinic Proceedings.
Author: Abhay Panchal
The article discusses several recent clinical trials in noncolorectal gastrointestinal cancer. Here’s a summary of the key trials mentioned: Advanced Hepatocellular Carcinoma Trial: This randomized placebo-controlled phase 2/3 study by the National Cancer Institute (NCI) is evaluating the effectiveness of a device called TheraBionic in treating advanced hepatocellular carcinoma. TheraBionic uses low levels of radiofrequency electromagnetic fields, delivered through a spoon-shaped antenna held in the patient’s mouth. The trial, which started recruitment in July 2023, aims to determine if this treatment can improve survival and quality of life in patients. Advanced Biliary-Tract Cancers Trial: An open-label, phase 3 trial is…
TORONTO—A novel artificial intelligence system accurately predicts esophageal stricture after endoscopic submucosal dissection for early esophageal cancer, according to a study by researchers from Japan. “This is one of a growing number of studies using AI to develop a prediction system,” Ronnie Fass, MD, the director of the Division of Gastroenterology and Hepatology at MetroHealth Medical Center and a professor of medicine at Case Western Reserve University, in Cleveland, told Gastroenterology & Endoscopy News. “What I find interesting about this particular system is that the investigators developed a model to identify risks and predict outcomes based on videos. This is…
A study presented at The Liver Meeting found a significant association between the consumption of ultra-processed foods (UPF) and the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) in both adolescents and adults. Here’s a summary of the key findings: Study Overview: The cross-sectional study analyzed data from 806 adolescents and 2,734 adults who participated in the 2017-2018 National Health and Nutrition Examination Survey. The researchers used two 24-hour dietary recalls to estimate UPF intake and diagnosed MASLD using transient elastography. Findings on UPF Consumption and MASLD Risk: Adolescents consumed an average of 810 grams of UPF per day, while…
The article from BioPharma Dive discusses AstraZeneca’s launch of a new health-tech business named Evinova. Here’s a summary of the key points: Evinova’s Launch and Focus: Evinova, operating as a separate business within AstraZeneca, aims to optimize clinical trials for biotechnology companies, pharmaceutical firms, and contract research organizations (CROs). Its primary goal is to reduce the time and costs associated with developing new medicines. Partnerships and Collaborations: Evinova has already established partnerships with two CROs, Parexel and Fortrea, to offer its digital health solutions to their customers. Additionally, it is collaborating with Accenture and Amazon Web Services to accelerate industry…
The research published in JAMA Network Open indicates that conventional colonoscopy is the most cost-effective method for colorectal cancer (CRC) screening in average-risk adults in the US, compared to circulating tumor DNA-based methods. Key points from the study include: Colonoscopy’s Cost-Effectiveness: The study, led by medical student Zainab Aziz under senior author Chin Hur at Columbia University Irving Medical Center, found that colonoscopy remains the most cost-effective tool for CRC screening. For liquid biopsy-based tests to be a viable option, they need to become more affordable and improve in detecting early-stage cancers and pre-cancerous lesions. Low Screening Rates in the…
The article reports on a lawsuit filed against Salem Hospital and Mass General Brigham. Here’s a summary of the key points: Notification of Potential Exposure: Salem Hospital in Massachusetts issued a warning to 450 endoscopy patients about a potential exposure to HIV and hepatitis. This exposure was due to incorrectly administered intravenous (IV) treatments. Class-Action Lawsuit Filed: A class-action lawsuit has been filed against Salem Hospital, Mass General Brigham, and 10 hospital employees. The lawsuit was filed on behalf of Melinda Cashman, a patient who claims to have been exposed to infection between June 2021 and April 2023. Allegations and…
The article details a legal action taken by Exact Sciences Corp. against Geneoscopy, Inc. Here’s a summary of the key points: Lawsuit Details: Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, has filed a lawsuit against Geneoscopy, Inc. in the United States District Court for the District of Delaware. The lawsuit seeks damages and a court order to prevent Geneoscopy from using, selling, or offering for sale its ColoSense product, which Exact Sciences claims infringes on its U.S. Patent No. 11,634,781. Patent Infringement Claim: The patent in question, ‘781, is utilized by Exact Sciences in its…
On the recent advancement in the treatment of primary sclerosing cholangitis (PSC). Here’s a summary of the key points: Fast Track Designation: The FDA has granted fast track status to Chemomab Therapeutics’ anti-CCL24 monoclonal antibody, CM-101, for the treatment of adults with primary sclerosing cholangitis. About CM-101: CM-101 is a first-in-class CCL24-neutralizing monoclonal antibody. It has been linked to crucial pathways in the underlying pathophysiology of primary sclerosing cholangitis. The antibody’s dual anti-inflammatory and anti-fibrotic activity aims to disrupt the cycle driving these pathways. CM-101 has shown promise as a disease-modifying therapy for PSC in preclinical and early clinical studies.…
Here’s a study evaluating the accuracy of ChatGPT, an artificial intelligence (AI) tool, in providing information about eosinophilic esophagitis (EoE). Here’s a summary of the key findings: Mixed Accuracy in Responses: The study found that ChatGPT’s responses to common questions about EoE were a mix of accurate and inaccurate. Notably, the AI provided incorrect information regarding the association between EoE and cancer. Complexity and Readability Issues: The responses from ChatGPT were found to have low readability and high complexity, potentially creating a barrier for users with different levels of health literacy. Implications for Clinical Use: The findings suggest caution in…